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population. The aim of the study was to evaluate the
impact of skin diseases on health state utlilities in the 
population. METHODS: A postal survey was carried out
on a sample of the population 20–84 years of age (n =
8000) of the county of Uppland, Sweden. Information on
dermatological problems was obtained by self-report.
Rating Scale was used to measure health state utilities.
RESULTS: The response rate was 68% (5404 individu-
als). A large proportion (20.5%) reported dermatological
problems and/or use of topical dermatological drugs. Skin
disease was evenly distributed over age but was more fre-
quent among women (23.3%) than among men (17.3%).
Persons reporting dermatological problems also reported
lower health state utility than others, 0.807 as compared
to 0.836 (p < 0.001). Dermatological problems had an
independent and statistically signiﬁcant (p < 0.01) effect
on utility when age, gender, somatic and psychiatric
comorbidity were included in a multivariate analysis.
CONCLUSIONS: The study shows that skin disorders
are a considerable problem in the population, and that
they do cause a decrease in health state utility as mea-
sured by the Rating Scale (RS). The result of this study
emphasizes the need for further epidemiological studies
analysing health state utilities in relation to severity and
type of skin disease.
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OBJECTIVES: New therapies for the treatment of severe
sepsis are in development and estimates are required 
of treatment costs, annual incidence and the national
burden-of-illness. This study concerns the Netherlands.
METHODS: Cost data were collected for 100 patients
consecutively admitted to a general hospital ICU from
1998 to 2000 for treatment of a ﬁrst episode of severe
sepsis. Costs were limited to direct medical ICU costs
from a societal perspective and collected with an activity
based information system. Annual incidence was esti-
mated with a point-prevalence survey in Dutch ICU’s, col-
lecting the clinical information concerning all patients at
the ICU on a single day. Patients were regarded as severely
septic if infection was present, two or more SIRS criteria
were fulﬁlled and when there was at least one dysfunc-
tional organ system. RESULTS: Daily costs were esti-
mated to be log-normally distributed with a mean of
€1,244 ± 404. ICU length of stay was estimated to be geo-
metrically distributed with a mean of 15.3 ± 15.8 days.
Total treatment costs were estimated at €19,509 ± 26,966
(log-normal). Main cost items were ﬁxed costs (43%),
nursing costs (28%), diagnostic tests (7%), medication
(5%), renal replacement therapy (5%) and blood (4%).
The presence of shock and/or renal failure was signiﬁ-
cantly associated with higher treatment costs, whereas
ICU survival only showed a trend towards increase.
Forty-seven ICU’s participated in the prevalence survey
and 143 patients were found to meet the criteria for
severe sepsis. The national incidence was estimated at
8,643 ± 929 patients per year. CONCLUSIONS: Costs of
severe sepsis treatment within the ICU are estimated at
€168.6 ± €29.5 million per year. This equals 1.7% of the
national hospital budget and 0.51% of all healthcare
expenses in 2000 in the Netherlands.
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OBJECTIVES: To determine and compare costs and cost
driving factors in the management of severe sepsis either
within a clinical trial setting or in daily practice.
METHODS: One hundred ﬁfty-two patients (from 4
Belgian centres) fulﬁlling criteria for severe sepsis between
1998 and 2000 were included in a chart review. Ninety-
one were clinical trial patients (rhAPC, TFPI or ATIII);
61 were non-trial patients. All healthcare costs (payers
perspective) between sepsis diagnosis and discharge were
collected from patient invoices by independent
researchers. RESULTS: Trial and non-trial patients were
comparable with regard to age, status (medical or surgi-
cal), underlying conditions including COPD, alcohol or
tobacco abuse and immunosuppression. Differences were
observed in mortality (45% versus 50%, trial versus non-
trial patients respectively), positive blood cultures (39%
versus 75%), renal replacement therapy (22% versus
31%), hypertension (41% versus 31%) cardiomyopathy
(16% versus 29%) cerebrovascular disease (5% versus
13%) and malignancy (19.8% versus 8%). There was no
difference (trial versus non-trial) in hospital (28 versus 27
days) or ICU length of stay (16 days both) after sepsis
diagnosis. Overall costs were similar in trial and non-trial
patients: €19,292 (St E:1,574) versus €16,314 (St E:
1,684) respectively. Multivariate regression (OLS on log-
transformed cost) revealed the following explaining
factors for total cost: death (neg. p = 0.003), pos. blood
culture (pos. p = 0.009), university hospital (pos. p =
0.035), mechanical ventilation (pos. p = 0.002) and renal
replacement therapy (pos. p = 0.002). The variable “trial
patient or not” revealed a p-value of 0.624. CONCLU-
SIONS: Factors inﬂuencing costs in severe sepsis include
death, pos. blood culture, university hospital setting,
renal replacement therapy and ventilation. Trial and non-
trial patients appear to be comparable with regard to
